End-of-day quote
Shanghai S.E.
06:00:00 2024-06-02 pm EDT
|
5-day change
|
1st Jan Change
|
20.69
CNY
|
+2.58%
|
|
-8.49%
|
-0.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,165
|
6,559
|
8,379
|
10,707
|
15,812
|
15,665
|
-
|
-
|
Enterprise Value (EV)
1 |
8,165
|
6,559
|
8,379
|
10,707
|
15,812
|
15,665
|
15,665
|
15,665
|
P/E ratio
|
18
x
|
14.4
x
|
16.5
x
|
27.7
x
|
35.4
x
|
26
x
|
19.5
x
|
16.5
x
|
Yield
|
-
|
-
|
-
|
-
|
0.96%
|
-
|
1.24%
|
-
|
Capitalization / Revenue
|
1.01
x
|
0.85
x
|
1.02
x
|
1.29
x
|
2.05
x
|
1.83
x
|
1.56
x
|
1.44
x
|
EV / Revenue
|
1.01
x
|
0.85
x
|
1.02
x
|
1.29
x
|
2.05
x
|
1.83
x
|
1.56
x
|
1.44
x
|
EV / EBITDA
|
-
|
9.2
x
|
10.4
x
|
15
x
|
21.1
x
|
16.9
x
|
13.8
x
|
11.8
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
1.47
x
|
1.75
x
|
2.15
x
|
2.98
x
|
2.69
x
|
2.39
x
|
2.16
x
|
Nbr of stocks (in thousands)
|
760,948
|
758,256
|
758,256
|
758,256
|
757,987
|
757,114
|
-
|
-
|
Reference price
2 |
10.73
|
8.650
|
11.05
|
14.12
|
20.86
|
20.69
|
20.69
|
20.69
|
Announcement Date
|
3/30/20
|
3/15/21
|
3/18/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8,120
|
7,717
|
8,254
|
8,282
|
7,703
|
8,578
|
10,014
|
10,842
|
EBITDA
1 |
-
|
712.9
|
806.8
|
713.2
|
749.2
|
924.5
|
1,134
|
1,327
|
EBIT
1 |
-
|
540.8
|
634
|
497.1
|
568.5
|
769.4
|
1,019
|
1,211
|
Operating Margin
|
-
|
7.01%
|
7.68%
|
6%
|
7.38%
|
8.97%
|
10.17%
|
11.17%
|
Earnings before Tax (EBT)
1 |
-
|
540.5
|
631.3
|
477.3
|
563.6
|
761.4
|
1,014
|
1,203
|
Net income
1 |
-
|
456.9
|
507.7
|
383.2
|
444.7
|
601.3
|
805.3
|
950.4
|
Net margin
|
-
|
5.92%
|
6.15%
|
4.63%
|
5.77%
|
7.01%
|
8.04%
|
8.77%
|
EPS
2 |
0.5965
|
0.6018
|
0.6695
|
0.5100
|
0.5900
|
0.7960
|
1.064
|
1.256
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
0.2000
|
-
|
0.2567
|
-
|
Announcement Date
|
3/30/20
|
3/15/21
|
3/18/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
10.6%
|
11%
|
7.89%
|
8.64%
|
10.3%
|
12.3%
|
13.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
4.68%
|
5.9%
|
7.16%
|
7.2%
|
Assets
1 |
-
|
-
|
-
|
-
|
9,499
|
10,191
|
11,247
|
13,199
|
Book Value Per Share
2 |
-
|
5.870
|
6.310
|
6.570
|
6.990
|
7.700
|
8.670
|
9.580
|
Cash Flow per Share
2 |
-
|
0.5400
|
0.3300
|
0.3300
|
0.4700
|
0.9100
|
1.120
|
1.370
|
Capex
1 |
-
|
46.6
|
226
|
65.5
|
57.1
|
132
|
123
|
136
|
Capex / Sales
|
-
|
0.6%
|
2.74%
|
0.79%
|
0.74%
|
1.54%
|
1.22%
|
1.25%
|
Announcement Date
|
3/30/20
|
3/15/21
|
3/18/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
20.69
CNY Average target price
25.01
CNY Spread / Average Target +20.88% Consensus |
1st Jan change
|
Capi.
|
---|
| -0.81% | 2.11B | | +42.60% | 739B | | +32.34% | 598B | | -5.74% | 353B | | +17.79% | 318B | | +3.37% | 285B | | +16.47% | 240B | | +9.26% | 210B | | -5.07% | 206B | | +6.74% | 164B |
Other Pharmaceuticals
|